Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00573651 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

A NA study of Arthritis, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
NA
Development phase
43
Enrollment target
4
Study locations

NCT00573651: Completed NA study of Arthritis, sponsored by University Hospitals Cleveland Medical Center.

NCT00573651 is a NA study of Arthritis that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 43 participants, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00573651, a NA study of Arthritis, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
NA
Development phase
43 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this research study is to see if patients with juvenile idiopathic arthritis or seronegative arthritis (and related conditions) mount protective immune responses to the human papillomavirus (HPV) vaccine called Gardasil. The researchers also want to monitor for any increase in disease activity following receipt of the vaccine.

Primary Outcome

dichotomized as negative or positive

Conditions Studied

Interventions

  • OTHER Blood Draws for Serum Titers

Study Locations (4)

Ohio

  • University Hospitals Medical Center - Cleveland
  • MetroHealth Medical Center - Cleveland
  • Cleveland Clinic - Cleveland

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2007-11
Est. Completion 2014-10-20
Phase NA

What the finished NCT00573651 record still lists

NCT00573651 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 4,509-participant average among 48 other Arthritis trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Blood Draws for Serum Titers is the first listed.

NCT00573651 reports a single indexed study location in Ohio, Illinois.

Frequently Asked Questions

What is clinical trial NCT00573651 about?

NCT00573651 is a clinical study titled "Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis". The purpose of this research study is to see if patients with juvenile idiopathic arthritis or seronegative arthritis (and related conditions) mount protective immune responses to the human papillomavirus (HPV) vaccine called Gardasil. The researchers also want to monitor for any increase in disease...

What is the current status of trial NCT00573651?

This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2007-11. Estimated completion is 2014-10-20.

What conditions does trial NCT00573651 study?

This clinical trial studies the following conditions: Arthritis.

What interventions are being tested in trial NCT00573651?

The interventions under investigation include: Blood Draws for Serum Titers (OTHER).

Who is sponsoring clinical trial NCT00573651?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00573651 being conducted?

This trial has 4 study locations across Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00573651's enrollment target sits among peer trials

43 34th of 48 higher than 15 of 48 other Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00573651, the US trial registry maintained by the National Library of Medicine. NCT00573651 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.